beta-Carotene inhibits rectal mucosal ornithine decarboxylase activity in colon cancer patients.
Colonic adenocarcinoma affects approximately 6% of adults in many Western countries. beta-Carotene (BC), a safe, inexpensive, and widely available compound, has been proposed as a cancer chemopreventive agent. To evaluate whether BC shows promise as an inhibitor of colonic carcinogenesis, we studied 20 male subjects who had previously undergone resection of colonic adenocarcinoma. Each subject received beta-carotene, 30 mg orally, daily for 6 months. Rectal mucosa was sampled at multiple intervals prior to, during, and following BC administration. Mucosal ornithine decarboxylase (ODC) activity and serum and mucosal BC concentrations were determined at each interval. ODC activity was inhibited by 44% (P < 0.05) and 57% (P < 0.01) after 2 and 9 weeks, respectively, of BC administration and remained low compared with baseline even 6 months following discontinuation of BC. Serum and mucosal BC concentrations increased as expected during BC administration and remained elevated for 6 months following BC discontinuation. The demonstrated inhibition of rectal mucosal ODC activity in these patients with resected colon cancer suggests that BC may prove useful as a cancer chemopreventive agent.
Phillips
R W
RW
Gastroenterology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001.
Kikendall
J W
JW
Luk
G D
GD
Willis
S M
SM
Murphy
J R
JR
Maydonovitch
C
C
Bowen
P E
PE
Stacewicz-Sapuntzakis
M
M
Wong
R K
RK
D000368:Aged; D002338:Carotenoids / Q000494:pharmacology*; D003110:Colonic Neoplasms; D006801:Humans; D007413:Intestinal Mucosa / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009955:Ornithine Decarboxylase / Q000378:metabolism; D065108:Ornithine Decarboxylase Inhibitors; D011446:Prospective Studies; D012007:Rectum / Q000201:enzymology* / Q000473:pathology*; D019207:beta Carotene
D065108:Ornithine Decarboxylase Inhibitors; D019207:beta Carotene; D002338:Carotenoids; D009955:Ornithine Decarboxylase